1-7 of 7
Kevin L Peterson
Close
Sort by
Journal Articles

Topoisomerase I-DNA Covalent Complexes in Myeloid Malignancies: A Potential Biomarker for Topoisomerase I Inhibitor Sensitivity

Mira A. Kohorst, MD, Karen S. Flatten, Kevin L. Peterson, Paula A. Schneider, Cristina Correia, Keith W. Pratz, MD, B. Douglas Smith, MD, Scott H. Kaufmann, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5146.
https://doi.org/10.1182/blood-2018-99-115667
Published: 2018
Journal Articles

4EBP1/c-MYC/PUMA and NF-κB/EGR1/BIM pathways underlie cytotoxicity of mTOR dual inhibitors in malignant lymphoid cells

Seongseok Yun, Nicole D. Vincelette, Katherine L. B. Knorr, Luciana L. Almada, Paula A. Schneider, Kevin L. Peterson, Karen S. Flatten, Haiming Dai, Keith W. Pratz, Allan D. Hess, B. Douglas Smith, Judith E. Karp, Andrea E. Wahner Hendrickson, Martin E. Fernandez-Zapico, Scott H. Kaufmann
Journal: Blood
Blood (2016) 127 (22): 2711–2722.
https://doi.org/10.1182/blood-2015-02-629485
Published: 2016
Includes: Supplemental data
Journal Articles

mTOR Dual Inhibitor Induced Cytotoxicity Depends on 4EBP1/c-Myc/Puma and NFkB/Egr-1/Bim Pathways in Human Lymphoid Malignancies

Seongseok Yun, MD PhD, Nicole D. Vincelette, Katherine L. B. Knorr, PhD, Luciana L. Almada, PhD, Paula A. Schneider, Kevin L. Peterson, PhD, Karen S. Flatten, Allan D. Hess, PhD, B. Douglas Smith, MD, Judith E. Karp, MD, Martin E. Fernandez-Zapico, MD, Scott H. Kaufmann, MD PhD
Journal: Blood
Blood (2015) 126 (23): 3705.
https://doi.org/10.1182/blood.V126.23.3705.3705
Published: 2015
Journal Articles

Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies

Mamta Gupta, Andrea E. Wahner Hendrickson, Seong Seok Yun, Jing Jing Han, Paula A. Schneider, Brian D. Koh, Mary J. Stenson, Linda E. Wellik, Jennifer C. Shing, Kevin L. Peterson, Karen S. Flatten, Allan D. Hess, B. Douglas Smith, Judith E. Karp, Sharon Barr, Thomas E. Witzig, Scott H. Kaufmann
Journal: Blood
Blood (2012) 119 (2): 476–487.
https://doi.org/10.1182/blood-2011-04-346601
Published: 2012
Includes: Supplemental data
Journal Articles

Cytotoxicity of farnesyltransferase inhibitors in lymphoid cells mediated by MAPK pathway inhibition and Bim up-regulation

Husheng Ding, Jennifer Hackbarth, Paula A. Schneider, Kevin L. Peterson, X. Wei Meng, Haiming Dai, Thomas E. Witzig, Scott H. Kaufmann
Journal: Blood
Blood (2011) 118 (18): 4872–4881.
https://doi.org/10.1182/blood-2011-02-334870
Published: 2011
Includes: Supplemental data
Journal Articles

OSI-027, a Dual TORC1/TORC2 Inhibitor, Induces Bim- and Puma-Mediated Apoptosis In Lymphoid Malignancy

Andrea E. Wahner Hendrickson, MD, Mamta Gupta, Ph.D, Seongseok Yun, Jennifer C. Shing, Paula A. Schneider, Kevin L. Peterson, Judith E. Karp, MD, Sharon Barr, Thomas E. Witzig, MD, Scott H. Kaufmann, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 970.
https://doi.org/10.1182/blood.V116.21.970.970
Published: 2010
Journal Articles

A Phase II Study of the Farnesyltransferase Inhibitor Tipifarnib Demonstrates Anti-Tumor Activity In Patients with Relapsed and Refractory Lymphomas

Thomas E. Witzig, MD, Tang Hui, PhD, Ivana N Micallef, MD, Stephen M. Ansell, MD, PhD, Brian Link, David James Inwards, MD, Luis Porrata, MD, Patrick B Johnston, MD, PhD, Joseph Colgan, Svetomir Markovic, MD, PhD, Grzegorz S. Nowakowski, MD, Carrie A Thompson, MD, Cristine Allmer, Matthew J Maurer, George Weiner, MD, Raymond J. Hohl, MD, PhD, Paul Kurtin, MD, Husheng Ding, PhD, Loegering A David, MD, Paula A Schneider, Kevin L Peterson, Thomas M. Habermann, MD, Scott H. Kaufmann, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 287.
https://doi.org/10.1182/blood.V116.21.287.287
Published: 2010